Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · IEX Real-Time Price · USD
-8.95 (-1.09%)
At close: Dec 1, 2023, 4:00 PM
-3.86 (-0.47%)
Pre-market: Dec 4, 2023, 7:11 AM EST
Market Cap 87.30B
Revenue (ttm) 13.10B
Net Income (ttm) 3.99B
Shares Out 107.13M
EPS (ttm) 35.05
PE Ratio 23.25
Forward PE 18.05
Dividend n/a
Ex-Dividend Date n/a
Volume 389,185
Open 824.94
Previous Close 823.81
Day's Range 808.89 - 828.42
52-Week Range 668.00 - 853.97
Beta 0.13
Analysts Buy
Price Target 913.09 (+12.06%)
Earnings Date Nov 2, 2023

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cuta... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 2, 1991
Employees 11,851
Stock Exchange NASDAQ
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2022, REGN's revenue was $12.17 billion, a decrease of -24.26% compared to the previous year's $16.07 billion. Earnings were $4.34 billion, a decrease of -46.28%.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $913.09, which is an increase of 12.06% from the latest price.

Price Target
(12.06% upside)
Analyst Consensus: Buy
Stock Forecasts


Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology ...

3 days ago - GlobeNewsWire

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence ...

7 days ago - GlobeNewsWire

Regeneron Announces Investor Conference Presentation

TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

18 days ago - GlobeNewsWire

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

Regeneron has sponsored ISEF - the world's largest high school science and engineering competition, and a program of Society for Science (Society) - since 2019

20 days ago - GlobeNewsWire

Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical stage biotechnology company developing a new form of local immunotherapy termed “anchored immunotherapy,” today announced a clinical ...

21 days ago - Business Wire

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma

4 weeks ago - GlobeNewsWire

Regeneron Pharma's adjusted earnings beat estimates

Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regeneron s...

4 weeks ago - Market Watch

Regeneron beats quarterly profit estimates on eczema treatment strength

Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.

4 weeks ago - Reuters

Regeneron Reports Third Quarter 2023 Financial and Operating Results

TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2023 and provided a business update.

4 weeks ago - GlobeNewsWire

EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient characteristi...

4 weeks ago - GlobeNewsWire

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron's first auditory program and is currently enrolling patients

5 weeks ago - GlobeNewsWire

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

5 weeks ago - GlobeNewsWire

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children

6 weeks ago - GlobeNewsWire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial

6 weeks ago - GlobeNewsWire

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a Com...

6 weeks ago - GlobeNewsWire

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

Commitment builds on Regeneron's longstanding efforts to develop the STEM talent pipeline as lead sponsor of the premier high school competitions, the Regeneron Science Talent Search (STS) and Regener...

6 weeks ago - GlobeNewsWire

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

NASHVILLE, Tenn. & TARRYTOWN, N.Y. & WILMINGTON, Del. & BAGSVAERD, Denmark & BASEL, Switzerland--(BUSINESS WIRE)--Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZ...

Other symbols: AZNNVORHHBY
6 weeks ago - Business Wire

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Event-free survival of investigational use of Libtayo ® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation

7 weeks ago - GlobeNewsWire

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years First presentation of long-term results demonstrated sustained...

2 months ago - GlobeNewsWire

Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies

Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases, ...

Other symbols: NTLA
2 months ago - Reuters

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

Collaboration combines Intellia's leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron's proprietary antibody-targeted viral vector delivery technologies to j...

2 months ago - GlobeNewsWire

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma

2 months ago - GlobeNewsWire

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursda...

2 months ago - GlobeNewsWire

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat

2 months ago - GlobeNewsWire

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., str...

2 months ago - GlobeNewsWire